International Journal of Medical Imaging

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Value of 18F-FDG PET-CT and MR Fusion in Preoperative Diagnosis and Staging of Pancreatic Cancer

Background: With the improvement of medical level, the incidence of some tumors decreased significantly; However, in the actual clinical work, it was found that the incidence and mortality of pancreatic cancer is increasing, and most of the findings are in the late stage, so the following studies have solved its current situation, so as to early detection, early treatment, improve the survival rate of patients; Secondly, better clinical staging, so as to reasonably select treatment methods. Objective: To use 18 fluoro-deoxyglucose (18F-FDG) positron emission computed tomography (PET-CT) molecular metabolism imaging and MRI multi-parameter structure imaging, and then use different machine fusion technology to realize the comprehensive application of pancreatic cancer diagnosis and staging. Methods: A retrospective comparative study was conducted on 100 patients with pancreatic space occupying diagnosed in our center. All patients received enhanced MR Examination and 18F-FDG PET-CT examination before surgery, and underwent different machine image fusion. Results: The sensitivity, specificity and accuracy of PET-CT and MRI in the diagnosis of pancreatic cancer were higher than those of PET-CT alone (P < 0.05). Conclusion: The PET-CT and MRI fusion technology can be used in the diagnosis of pancreatic cancer, which can be accurately staged and provide help for early clinical diagnosis and treatment.

18F-FDG PET/CT, Pancreatic Cancer, MRI Imaging Technology, Different Machine Fusion

Yang Xiu-jin. (2023). Value of 18F-FDG PET-CT and MR Fusion in Preoperative Diagnosis and Staging of Pancreatic Cancer. International Journal of Medical Imaging, 11(2), 30-33.

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Pan S B, Zhao H C, Xie K, et al. The value of enhanced CT and PET /CT in the diagnosis and staging of pancreatic cancer [J]. Hepatobiliary Surgery, 2013; 21 (6): 453-6.
2. Wei GH, Sun XG, Liu JJ, et al. The value of 18F-FDG PET/CT in diagnosis and treatment of pancreatic malignant tumor [J]. Zhonghua He Yi Xue Yu Fen Zi Ying Xiang Za Zhi, 2009, 29 (1): 23-6.
3. Kikuyama M, Kamisawa T, Kuruma S, et al. Early diagnosis to improve the poor prognosis of pancreatic cancer [J]. Working (Basel), 2018, 10 (2): E48. DOI: 10.3390/cancers10020048.
4. Tang K, Lu W, Qin W, et al. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages [J]. Pancreatology, 2016, 16 (1): 28-37. DOI: 10.1016/j.pan.2015.11.007.
5. Ma Kaiqi, Xue Huanzhou, et al. Diagnostic value of MRI and PET-CT in early pancreatic cancer. Clinical Medicine, Jan. 2019, Vol. 39, No 1.
6. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness [J]. Ann Surg, 2005, 242 (2): 235-43.
7. Zheng Lichun, Zhang Wenjun, Liu Guichao, et al. Differential diagnosis of benign and malignant pancreatic lesions by PET / CT, MRI and combined application [J]. J Hebei Medical University, 2016, 37 (5): 562-566. (in Chinese) DOI: 10.3969/j.issn.1007-3205.2016.05.017.
8. Zhang WJ. Application of 18F-FDG PET-CT in pancreatic cancer [D]. Beijing Xie He Yi Xue Yuan, 2012. (in Chinese)
9. Sperti C, Pasquali C, Decet G, et al. F-18 - fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study [J]. J Gastrointest Surg, 2005, 9 (1): 22-28. DOI: 10.1016/j.Jassur.2004.10.002.
10. Peng Zhao-qiao, Bai Bo, WU Jing-ming, et al. PET+CT+MR "two-machine three-dimensional" image fusion based on body surface localization and its significance in orthopedic diagnosis [fJ/CD]. Chinese Journal of Joint Surgery: Electronic Edition, 2011, 5 (3): 350-357.
11. Tian Ming, Yan Jun, Hu Jinjing, et al. Prevalence and risk factors of pancreatic cancer [J]. Chinese Journal of Social Medicine, 2016; 33 (2): 137-40.
12. Bochatay L, Girardin M, Michard P, et al. Pancreatic cancer in 2014: screening and epidemiology [J]. Rev Med Suisse, 2014; 10 (440): 1582-5.
13. Li Fei, Fu Min. CA19-9, CEA and CA125 combined with B-ultrasound, enhanced CT and MRI in the diagnosis of pancreatic cancer [J]. Sichuan Med, 2013, 34 (7): 926-928. (in Chinese) DOI: 10.3969/j.issn.1004-0501.2013.07.014.
14. Zhang WW, Hao BL, Wang Z, et al. (18) The value of F-deoxyglucose PET /CT and enhanced CT in the differential diagnosis of pancreatic cancer [J]. Journal of Clinical Military Medicine, 2017, 45 (10): 1035-1038. DOI: 10.16680/j.1671-3826.2017.10.13.
15. Yu ZF, Fang Y, Zhang J, et al. Comparative study of 18F-FDG PET/CT and contract CT in diagnosing and staging assessment of pancreatic canner [J]. Yi Xue Ying Xiang Xue Za Zhi, 2013, 23 (8): 1236-40.
16. Wang ZG, Shi QX, Gui J, et al. Clinical Value of CA19-9, Chuang, 2014, 21 (5): 507-10.
17. Kauhanen S, Rinta-Kiikka I, Kemppainen J, et al. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study [J]. J Nucl Med, 2015, 56 (8): The 1163-8.
18. Nagamachi S, Nishii R, Wakamatsu H, et al. The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT [J]. Ann Nucl Med, 2013, 27 (6): 554-63.
19. Salavati A, Saboury B, Alavi A, et al. Com ment on: tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET /CT [J]. J Nucl Med, 2014; 55 (2): 350-1.
20. Fang Y, Zhang J, Cui Y, et al. Value of dual-time-point 18F-FDG PET/CT in differential diagnose of pancreatic disease [J]. Yi Xue Ying Xiang Xue Za Zhi, 2013, 23 (11): 1733-5.
21. Buchs NC, Buhler L, Bucher P, et al. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study [J]. J Gastroenterol Hepatol, 2011, 26 (4): 657-62.